搜尋
Vyne Therapeutics Inc
VYNE添加自選
0.681USD
+0.030+4.66%
收盤 07/01, 16:00（美東）報價延遲15分鐘
22.71M總市值
虧損本益比TTM
關於 Vyne Therapeutics Inc 公司
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc簡介
公司代碼VYNE
公司名稱Vyne Therapeutics Inc
上市日期Jan 25, 2018
CEODomzalski (David)
員工數量13
證券類型Ordinary Share
年結日Jan 25
公司地址685 Route 202/206 N., Suite 301
城市BRIDGEWATER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編08807
電話18007757936
網址https://vynetherapeutics.com/
公司代碼VYNE
上市日期Jan 25, 2018
CEODomzalski (David)
Vyne Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
常見問題
Vyne Therapeutics Inc的前五大股東是誰？
Vyne Therapeutics Inc的前五大股東如下：Mr. Tyler Zeronda
有多少機構持有Vyne Therapeutics Inc(VYNE)的股份？
截至2026Q1，共有92家機構持有Vyne Therapeutics Inc的股份，合計持有的股份價值約為11.08M，占公司總股份的33.26% 。與2025Q4相比，機構持股有所增加，增幅為-1672969.00。